Zoomability publicerade den 20 februari 2025 bolagets delårsrapport för årets fjärde kvartal 2024.
Redeye updates its estimates and valuation following the Q4 2024 report from Cheffelo.
Titania publicerade den 20 februari år 2025 Bolagets delårsrapport för det fjärde kvartalet år 2024.
Redeye provides a research update following the Q4 report published by OncoZenge earlier today.
Prostatype Genomics har kompletterat sin ansökan om att inkluderas i det amerikanska ersättningssyst...
Fastighetsbolaget Trianon avslutar året med ett starkt resultat om cirka 200 (-314,5) miljoner krono...
Redeye comments on Medivir’s final phase IIa data of fostrox + Lenvima in second-line liver cancer (...
Redeye is positive to the news that EMA has returned with positive feedback to IRLAB’s phase III pla...
Nosa Plugs AB ("Nosa Plugs" or the "Company") is a medical technology company that has developed int...
Redeye’s initial comments on the Q4 report from Waystream.
Redeye states InfraCom’s Q4 2024 report came in better than anticipated and is another print showing...
Redeye provides its initial take on Navigo’s Q4 2024 report, which beat our sales estimate but misse...
Redeye comments on Fable Media Group’s Q4 results, which were in line with expectations.
Redeye’s first comments on the Q4 report this morning.
'25e-'26e adj. EBITA down 3% Latent working capital release likely in Q1'25 '25e EV/EBITA of 9x is ~...
Redeye comments on Teneo AI’s Q4, aligning strong preliminary figures showing a rapid acceleration i...
Redeye comments on Better Collective’s Q4-results and given the preannounced revenue and EBITDA outc...
Redeye updates its view on Nanologica following the year-end report and recent news flow.
Redeye comments on Th1ng’s latest turmoil—shareholder revolt, board shake-up, and the founder’s ret...
Net sales were EUR ~104m and EBITDA came in at EUR ~2m in Q4 2024, according to preliminary informat...